HepC Inc

We develop a clinically proven revolutionary antiviral biologic product, which is safe and effective against the unrelated hepatitis B and C viral infections.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Budapest, Hungary
  • Currency HUF
  • Founded December 2005
  • Employees 0
  • Incorporation Type S-corp
  • Website hepcinc.com

Company Summary

HepC's viral superinfection therapy (SIT) is a platform technology that exploits viral competition for the treatment of acute and persistent viral infections. SIT could be developed into the first technological platform, which will be registered for the “one-drug-multiple-bugs” treatment approach of viral diseases.
Our strategy is to complete a Phase I/II clinical trial in HBV and HCV patients with unmet needs in the shortest possible time frame.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free